Trial reportOpen heart2025
Association of serum potassium time in target range with cardiovascular outcomes in patients with HFpEF.
Trial report in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00094302 (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum potassium (sK) disorders are associated with worse outcomes in patients with heart failure with preserved ejection fraction (HFpEF). This study introduced a novel metric, time in target range (TTR), for long-term monitoring of sK levels and determined its prognostic value in patients with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.
methodsThe TTR for sK levels was defined as the percentage of time during which the sK was within the target range of 4.3-4.9 mmol/L, and was estimated using linear interpolation based on at least five valid measurements of sK. The association between sK TTR and cardiovascular (CV) events was estimated using adjusted Cox proportional hazards regression models.
resultsA total of 3141 TOPCAT participants with HFpEF were evaluated over a median follow-up period of 3.9 years. A greater time within the range of 4.3-4.9 mmol/L for sK was associated with a lower risk of CV events in patients with HFpEF (HR: 0.712; 95% CI: 0.571 to 0.889). The benefits remained when the range of sK was set at 4.3-4.6, or 4.6-4.9, while no benefits or even negative effects were observed at 4.0-4.3, or 4.9-5.2 mmol/L. The association between a higher TTR and lower risk of CV outcomes was consistent across subgroups. The sK TTR predicted a lower risk of CV events, even after adjusting for traditional CV risk factors, mean sK and sK variability.
conclusionMaintaining sK levels within the range of 4.3-4.9 mmol/L most of the time in patients with HFpEF is associated with a lower risk of CV events or all-cause mortality. TRIAL REGISTRATION NUMBER: NCT00094302.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.